After a pivotal and transformative 2025, Zymeworks Inc. (ZYME) expects its 2026 milestones and priorities to drive long-term value creation.
Following the announcement, ZYME is trading 2.72% higher in the pre-market at $23.80.
The company's wholly owned lead drug candidate is ZW191, which is under a phase 1 trial in patients with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.